Plate Nº 37 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Semaglutide Linked to 21% Lower Psychiatric Hospitalization Risk
A Swedish study of nearly 15,000 people with bipolar disorder links semaglutide, the drug in Ozempic and Wegovy, to a 21% lower risk of psychiatric hospitalization.
By Elena Vasquez3 min read581 words
In brief
- Semaglutide use was associated with a 21% lower risk of psychiatric hospitalization in bipolar disorder.
- The study covered nearly 15,000 patients in Swedish nationwide data from 2009 to 2024.
- Liraglutide and dulaglutide did not show the same association.
- The paper was published in Acta Psychiatrica Scandinavica on September 8, 2026.
- Roughly 37 million people worldwide live with bipolar disorder, per WHO estimates.
People with bipolar disorder who took semaglutide — the active ingredient in Ozempic and Wegovy — showed a 21% lower risk of psychiatric hospitalization, according to a large Swedish study published September 8, 2026, in Acta Psychiatrica Scandinavica.
Researchers at Griffith University analyzed nationwide Swedish health data covering nearly 15,000 people with bipolar disorder who had been prescribed GLP-1 medications over a 15-year period, from 2009 to 2024. GLP-1 receptor agonists, as the drug class is formally known, mimic a gut hormone that regulates blood sugar and appetite. Doctors already prescribe them widely for diabetes and weight loss.
What did the study find?
The team, led by Professor Mark Taylor of Griffith's School of Medicine and Dentistry, compared hospitalization rates during periods when patients were taking the drugs with periods when they were not.
"People with bipolar disorder who were taking semaglutide (otherwise known as Ozempic or Wegovy), a type of GLP-1 medication, had significantly lower rates of psychiatric hospitalization compared with periods when they were not taking GLP-1 medicines," Professor Taylor said.
The key numbers:
- 21% lower risk of psychiatric hospitalization associated with semaglutide use
- Nearly 15,000 patients with bipolar disorder included in the analysis
- 15 years of data, spanning prescriptions from 2009 to 2024
Notably, the benefit did not extend across the whole drug class. Two other GLP-1 medications, liraglutide and dulaglutide, showed no association with reduced psychiatric hospitalization risk.
Why might a diabetes drug affect mood?
The biology of bipolar disorder, diabetes, and obesity overlaps more than researchers once assumed. The three conditions frequently occur together and may share underlying mechanisms.
The study authors suggest GLP-1 signaling could help protect the brain by reducing inflammation and cellular stress — biological processes associated with bipolar disorder. In theory, these effects could contribute to greater mood stability and a lower risk of relapse.
This is a proposed mechanism, not a proven one. The study observed an association; it cannot establish that semaglutide directly improves psychiatric outcomes.
How strong is the evidence?
The findings come from observational data, which means researchers tracked what happened to patients in the real world rather than assigning treatments by chance. Such studies can reveal patterns but cannot rule out other explanations for the difference in hospitalization rates.
Professor Taylor acknowledges this limitation. He said the findings "add to growing evidence that GLP-1 receptor agonists may have benefits beyond diabetes and obesity treatment, and could represent a promising new avenue for bipolar research," but he hopes the work will now be tested in a randomized controlled trial — the gold-standard design that could show whether semaglutide itself improves psychiatric outcomes.
Why it matters
Bipolar disorder affects roughly one in 200 people worldwide, about 37 million individuals, according to the latest World Health Organization estimates. Existing treatments help many patients, but relapses requiring hospitalization remain common.
If a drug already approved for diabetes and obesity could also stabilize mood, the clinical implications would be substantial. That possibility, however, remains preliminary until clinical trials confirm it.
For now, patients should not change any medication routine on the basis of this study. Anyone with questions about GLP-1 drugs and mental health should discuss them with their prescribing doctor.
The paper, 'Use of glucagon-like peptide 1 receptor agonists and the associated risk of hospitalisation in bipolar disorder, from a nationwide cohort, 2009–2024,' was authored by Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer-Rutz, Antti Tanskanen, and Jari Tiihonen.
via news.griffith.edu.au (Original)
More from Elena Vasquez
Nearby plates
- Quitting Ozempic for Two Years Raises Heart Risk by 22%
- Cleveland Clinic Examines What Happens After GLP-1 Discontinuation
- Lancet Publishes Results of Semaglutide Trials in Early Alzheimer's
- GLP-1 Diabetes Drugs Show Real-World Benefits in Young People
- Large Nordic Study Finds No Link Between Semaglutide and Pancreatic Cancer